Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE ACETATE versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE ACETATE versus KENALOG IN ORABASE.
DEXAMETHASONE ACETATE vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
0.5-9 mg/day orally in divided doses every 6-12 hours; intravenously or intramuscularly as dexamethasone sodium phosphate; typical anti-inflammatory dose 0.75-9 mg/day. For cerebral edema: IV loading dose 10 mg, then 4 mg every 6 hours. For COVID-19: 6 mg IV or orally once daily for up to 10 days.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in adults; slightly prolonged in neonates (approximately 12-24 hours) and patients with hepatic impairment. Clinical context: Duration of HPA axis suppression may exceed the presence of measurable drug; single dose typically suppresses cortisol for 24-36 hours.
Terminal half-life approximately 2-5 hours following mucosal application.
Renal (primarily as glucuronide and sulfate conjugates) and biliary/fecal (minor). Approximately 65-80% of a dose is excreted in urine within 24 hours as 20-beta-dihydrodexamethasone (inactive) and conjugated metabolites; about 10-15% appears in feces. Less than 5% is excreted unchanged.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category D/X
Category C
Corticosteroid
Corticosteroid